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SUMMARY – Lupus nephritis (LN) is one of the most severe features of systemic lupus erythe-
matosus (SLE). Data on LN is scarce in the Croatian population. We analysed the characteristics of 
LN patients diagnosed at our tertiary referral centre. In this retrospective study, we analysed the fol-
lowing features of patients with biopsy-proven LN diagnosed between 2011 and 2020: demographics, 
renal laboratory parameters, renal histopathology, and treatment.
A total of 38 patients were included (30 females; mean age 39±15 years). The most common indi-
cation for kidney biopsy was proteinuria (89%). The proportion of LN classes was: class I (2.6%), II 
(5.3%), III (18.4%), IV (42.1%), V (13.2%), III+V (10.5%), IV+V (5.3%). The median time from SLE 
diagnosis to histologic confirmation of LN was 1.0 year. All patients were treated with methylpred-
nisolone (MP), 68% received MP pulses. Induction treatment included intravenous (IV) cyclophos-
phamide (CYC) (71%) (15 patients treated per Euro-Lupus and 9 per the National Institutes of 
Health regimen), oral CYC (3%), or mycophenolate mofetil (11%). 79% of patients received antima-
larials. While there is heterogeneity between different populations, our patient profile was similar to 
that from other European studies. Further follow-up of this group is necessary to assess outcomes in 
our population.
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Lupus nephritis (LN), a severe manifestation of 
systemic lupus erythematosus (SLE), affects around 
40 to 50% of SLE patients and can range from silent 
nephritis (subclinical illness) to end-stage renal disease 
(terminal illness)1 Recent studies revealed that the 5- 
and 15-year risk of ESRD equals 11% and 22%, re-
spectively, and that around 10-30% of LN patients 
progress to kidney failure requiring renal replacement 
therapy, with higher percentages being seen in prolif-
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erative LN.1,2 The clinical course of SLE can vary from 
benign illness to a rapidly progressive disease with or-
gan failure and death. Patients with SLE have mortal-
ity rates ranging from two to five times higher than 
that of the general population, with renal disease as-
sociated with the highest mortality risk.3,4 SLE pa-
tients with renal damage and ESRD have a 14-fold 
and more than 60-fold, respectively, increased risk of 
premature death.5,6 In a study of 10-year mortality 
from our SLE cohort (2002-2011), LN was associated 
with a 2.46-fold increased risk of death (odds ratio, 
95% confidence interval 1.13-5.37).7 Biopsy is the key 
diagnostic procedure in evaluating these patients and 
histopathology is crucial in determining the classifica-
tion, management, and prognosis of LN. LN is consid-
ered a chameleon of renal pathology, so the histologic 
classification of LN is required to accurately define the 
degree of kidney injury associated with SLE, to guide 
treatment and predict outcomes.8 The International 
Society of Nephrology/Renal Pathology Society clas-
sification for lupus nephritis (ISN/RPS) published in 
2003, reports definitions and classification of glomeru-
lar lesions in LN. Lupus nephritis is immune-com-
plex-mediated glomerulonephritis (GN) and is classi-
fied into six patterns or classes. In SLE patients with 
renal injury, it is of great importance to exclude other 
mechanisms of kidney injury such as thrombotic mi-
croangiopathy and lupus podocytopathy which can be 
seen in up to 24% and 1.3% of LN patients, respec-
tively. The finding of isolated tubulointerstitial nephri-
tis is becoming increasingly recognized.9,10 A number 
of studies have found that both SLE and LN show 
different characteristics and that there might be im-
portant heterogeneity in patient characteristics and 
outcomes, especially in LN which comprises patients 
with the most difficult clinical course.11–15 The ALMS 
study (Aspreva Lupus Management Study) was one of 
the first studies to systematically explore the potential 
effect of race/ethnicity on LN treatment. The study re-
ported that race, ethnicity, and geographical region 
might influence the therapeutic response and that 
some ethnicities had a varied response to different 
types of therapy, heralding the future need for person-
alized treatment.16,17 Subsequent studies confirmed 
this concept both in SLE and LN.13,18 A recent large 
cross-sectional study enrolling a multiethnic cohort of 
1244 SLE patients (48.7% had concurrent LN) of 
Northern and Southern European, Hispanic, African 
American, and East Asian descent genotyped for 
817,810 single-nucleotide polymorphisms (SNPs) 
across the genome demonstrated distinct genetic fac-
tors which varied with ethnicity and might be respon-
sible for heterogeneity in clinical characteristics and 
response to therapy.12 Data on the characteristics of 
LN patients and therapeutic strategies used in South-
Eastern Europe are scarce. Only one well-designed 
study has been published on the Croatian population 
thus far, reflecting the diagnostic and therapeutic ap-
proach that was currently more than two decades 
ago.19 Therefore, the aim of this study is to describe the 
demographic, clinical, laboratory, and histopathologi-
cal characteristics and current therapeutic strategies in 
LN patients in Croatia, using data from the National 
Referral Centre for SLE.
Subjects and Methods
Subjects
This retrospective study included all adult patients 
(>18 years of age) with a diagnosis of SLE and a biop-
sy-proven LN of any class who underwent biopsy in 
the Kidney Biopsy Unit of our institution, UHC Za-
greb, a tertiary, university hospital and in the National 
referral centre for SLE, between January 2011 and 
January 2020. All patients met the 1997 revised Amer-
ican College of Rheumatology (ACR) classification 
criteria for SLE.20 There were no general or specific 
exclusion criteria except data completion, i.e., available 
data on performed biopsy. Kidney biopsy was per-
formed in patients with worsening proteinuria, labora-
tory signs of decline in kidney function, or active urine 
sediment presence.21 For each patient, we obtained and 
analysed general and disease-specific demographic 
data at the time of kidney biopsy, as well as 24-hour 
proteinuria and characteristics of the urine sediment 
before kidney biopsy. Data obtained from the kidney 
biopsy specimen was also analysed, as well as treat-
ment regimens used in each patient. All data were ob-
tained during routine patient workup, without the 
need for any additional examinations. The data are 
stored in the database of the National Referral Centre 
for Systemic Lupus Erythematosus and Related Dis-
eases within our institution. Ethical approval for this 
study was obtained from the Ethical Committee of the 
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University Hospital Centre Zagreb (02/21 AG). The 
procedures followed were in accordance with the ethi-
cal standards of the Helsinki Declaration of 1975, as 
revised in 1983.
Histopathology
Samples for histological analysis were obtained us-
ing the ultrasound-guided percutaneous needle biopsy 
method, or in some cases, under the control of com-
puted tomography (CT). All adequate samples with 
renal tissue containing glomeruli were routinely pro-
cessed for light microscopy (LM), immunofluores-
cence (IF), and electron microscopy (EM). Samples 
for light microscopy were serially cut and stained with 
haematoxylin and eosin, periodic acid–Schiff, Mallory 
trichrome, elastica, and Jones methenamine silver 
stain. Part of the tissue with glomeruli was frozen, sec-
tioned, and processed for direct immunofluorescence 
(IF) using immunofluorescent antibodies against IgA, 
IgG, IgM, C3, C1q fibrinogen, kappa, and lambda 
light chains. Small cortical tissue pieces with at least 
one glomeruli were additionally analysed by use of 
transmission electron microscopy. Kidney biopsies 
were classified according to the 2003 ISN/RPS criteria 
system, and activity and chronicity indexes were based 
according to the scoring system from the National In-
stitutes of Health.8 The ISN-RPS classification of lu-
pus nephritis is composed of six classes based on glo-
merular findings and the establishment of patterns of 
immune complex-mediated glomerular injury, which 
is the most common form of renal involvement in 
SLE. Lupus classes are further subdivided using sev-
eral modifiers such as focal vs. diffuse glomerular in-
volvement, global vs. segmental glomerular injury, as 
well as whether the glomerular injury is active or 
chronic. Class I is defined as minimal mesangial lupus 
nephritis with mesangial immune deposits detected 
by IF and/or EM but without mesangial hypercellu-
larity on LM. Class II represents mesangioprolifera-
tive LN, while classes III and IV denote proliferative 
forms of lupus nephritis. Class III is defined as focal 
lupus nephritis involving <50% of affected glomeruli 
and distinguishes it from class IV, characterized by dif-
fuse glomerulonephritis involving >50% of a total 
number of glomeruli. Class IV consists of either seg-
mental (class IV-S) or global (class IV-G) involvement 
and can also have active or sclerotic lesions. Class V 
stands for membranous lupus nephritis, and class VI 
for advanced sclerosing lesions affecting >90% of 
glomeruli. Combinations of membranous and prolif-
erative glomerulonephritis are possible and are classi-
fied as either class III and V or class IV and V.8
Statistical analysis
Normality was assessed using the D’Agostino-Pear-
son test. Continuous variables were presented as mean 
and standard deviation if normally distributed and as 
median and interquartile range if non-normally distrib-
uted. Categorical data were presented as absolute values 
and proportions. To assess differences between genders, 
variables were compared between female and male pa-
tients with LN. Normally distributed data were com-
pared using Student’s t-test and non-normally distrib-
uted using Mann-Whitney U-test. The distribution of 
categorical data across groups was compared using 
Fisher’s exact test. Statistical significance was defined 
with a two-sided p-value<0.05. Data analysis was done 
using SPSS v. 23 (IBM Corp., USA).
Results
We have enrolled 38 patients (30 females and 8 
males, mean age 37±13 years) with biopsy-proven LN. 
When examining the time of onset of LN, i.e., early-
onset (patients diagnosed within <5 years following 
diagnosis) vs. late-onset LN, 75% had early-onset and 
25% had late-onset LN. There was no difference in 
time from diagnosis of SLE to confirmation of LN or 
the proportion of patients having LN diagnosis in the 
first year of SLE (males vs. females, 50% vs. 53%, re-
spectively, p=0.77). Demographic and clinical charac-
teristics and comparison between females and males 
are presented in Table 1. The most common indication 
for kidney biopsy was proteinuria (89%), followed by a 
decline in kidney function (8%), and glomerular hae-
maturia (3%). Mean proteinuria at the time of biopsy 
was 4.2±3.1 g/day and ranged from 0.1 to 10.8 g/day. 
There was no statistical significance in the frequency of 
nephrotic proteinuria between genders (females vs. 
males, 43% vs. 63%, p=0.44), but males tended to have 
non-significantly higher proteinuria (females vs. males, 
3.8±3.0 vs. 5.6±3.5, respectively, p=0.14). A total of 20 
(53%) patients had non-nephrotic proteinuria (<3.5 g/
day, of which 3 patients with proteinuria<500 mg/day) 
and 18 (47%) had nephrotic proteinuria. The median 
time from SLE diagnosis to histologic confirmation of 
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Figure 1. Glomerulus with mesangial hypercellularity, 
global endocapillary proliferation and fibrocellular 
crescent in LN Class IV (PAS stain, magnification 200x).
Figure 2. Segmental endocapillary proliferation and 
thickening of glomerular basal membranes in LN class 
III-V (PAS stain, magnification 200x).
Table 1. Demographic and clinical characteristics of the group and comparison between females and males.
Characteristic Whole group (N=38) Females (N=30) Males (N=8) p*
Age at diagnosis of LN (years) 37±13 37±13 37±12 0.97
Age at diagnosis of SLE (years) 33±14 32±14 34±15 0.75
Time from diagnosis of SLE to LN (years) 4.4±6.71 (0 - 5.5)
4.4±6.8
1 (0 - 6)
4.0±6.7
1 (0 - 5) 0.84
Indication for biopsy
0.76
Proteinuria 34 (89) 27 (90) 7 (88)
Decline in kidney function 3 (7) 2 (7) 1 (12)
Glomerular hematuria 1 (3) 1 (3) 0 (0)
LN Class
0.88
I 1 (2.6) 1 (3.3) 0 (0)
II 2 (5.3) 2 (6.7) 0 (0)
III 7 (18.4) 6 (20.0) 1 (12.5)
IV 16 (42.1) 13 (43.3) 3 (37.5)
V 5 (13.2) 2 (6.7) 3 (37.5)
III+V 4 (10.5) 4 (13.3) 0 (12.5)
IV+V 2 (5.3) 2 (6.7) 0 (0)
VI 0 (0) 0 (0) 0 (0)
Unclassified 1 (2.6) 0 (0) 1 (12.5)
Induction therapy
0.80
Cyclophosphamide + MP 28 (74) 24 (80) 4 (50)
MMF + MP 6 (16) 4 (13) 2 (25)
Other 3 (8) 2 (7) 1 (12.5)
None 1 (2) 0 (0) 1 (12.5)
*p-value for comparison between males and females; values present either absolute count (percentage), mean ± standard deviation or  median 
(interquartile range); MP – methylprednisolone, MMF – mycophenolate mophetil, SLE – systemic lupus erythematosus, LN – lupus 
 nephritis
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LN was 1.0 year (IQR 0.0 to 5.25 years, mean 4.4±6.6 
years). Prevalence among LN classes was: class I 
(2.6%), II (5.3%), III (18.4%), IV (42.1%), V (13.2%), 
III+V (10.5%), IV+V (5.3%) and unclassified (2.6%) 
(Figures 1 and 2; Table 1). Patients were treated with 
cyclophosphamide iv. + methylprednisolone (74%), 
 cyclophosphamide po. + methylprednisolone (3%), 
MMF + methylprednisolone (16%), other or none 
(10%). Among the patients treated with intravenous 
cyclophosphamide, 15 patients received induction per 
Euro-Lupus (i.e., six bi-weekly applications of 500 mg 
cyclophosphamide) and 9 per the NIH regimen (i.e., 
six-monthly applications of 1000 mg cyclophospha-
mide). A total of 68% of patients received methylpred-
nisolone pulses (≥250 mg, for three subsequent days). 
The average cumulative dose of cyclophosphamide was 
4048±1934 mg. When looking at maintenance thera-
py, all patients received oral corticosteroids combined 
with MMF (47%), azathioprine (14%), cyclophospha-
mide (14%), cyclosporine (11%), rituximab (3%), and 
other immunosuppressants (11%). A total of 79% of 
patients received antimalarial drugs. Eight patients re-
ceived immunoglobulins and two underwent thera-
peutic plasma exchange.
Discussion
This retrospective study aimed to present demo-
graphic and clinical characteristics of LN patients 
from Croatia. Our patients were predominantly fe-
males (79%), which is in line with studies conducted 
worldwide, including United States22, Spain23, Serbia24, 
Taiwan25, Brazil26, India27. Conversely, studies con-
ducted in cohorts of patients with LN did not have 
such a pronounced female predominance. Compared 
to the male to female ratio in the overall population of 
SLE patients, a relatively higher proportion of males 
was reported in most of the large LN cohorts (male vs. 
female, 27–75% vs. 16–52%, respectively; male-to-fe-
male ratio ranging from 1.1:1 to 1.7:1). Interestingly, 
the male to female ratio has not been shown to vary 
with ethnicity.28–32 It seems that males exhibit a higher 
risk of renal affection, despite the overall higher pro-
portion of females being afflicted by SLE in general.33 
The mean age of our LN patients was 37 years (rang-
ing from 19 to 64 years), which is consistent with a 
large Medicaid-based study on adult SLE patients, 
which reported that 50.1% of patients were aged 30 to 
49 years and 91.8% were aged 18 to 49 years. Com-
pared to patients with lupus nephritis, the whole group 
of SLE patients was somewhat older and aggregating 
less in the 18 to 29 age group (LN vs. SLE, 41.7% vs. 
27.7%, respectively).34 A large international multieth-
nic cohort also reported a relatively young age at onset 
of LN (31.3 years)33, as did a Spanish study of 933 
patients with LN (28.4 years).23 Several further studies 
also reported younger age at diagnosis of LN when 
compared to the age at diagnosis of non-nephritic 
SLE.33,35,36 In our group, LN was most commonly con-
firmed in the first year after SLE diagnosis (17 out of 
a total of 34 patients with a known year of both SLE 
and LN diagnosis), however with a wide time range 
and a mean time from diagnosis of SLE to confirma-
tion of LN of 4.4 years. The findings of several studies 
are in line with this observation of LN presenting ear-
ly in the disease course of SLE. Galindo-Izquierdo et 
al. reported that 56.3% of patients had LN diagnosed 
in the first year following SLE onset23, while Seligman 
et al. identified a gender-specific difference with a 
higher proportion of males reaching the diagnosis of 
LN in the first year (males vs. females, 47% vs. 20%, 
respectively).37 We were not able to confirm a gender-
specific difference in this aspect (females vs. males, 
50% vs. 53%). A very recent study by Delfino et al. 
aimed to identify differences between early-onset LN 
(defined as LN occurring within <5 years from diag-
nosis of SLE) and late-onset LN (diagnosis of LN af-
ter ≥5 years of SLE diagnosis). The study found that 
the majority of LN occurred early (70.4%) but identi-
fied no difference in disease characteristics or treat-
ment outcomes.38 In our study, 75% of LN patients 
were diagnosed within <5 years following diagnosis of 
SLE, and it will be interesting to explore the differ-
ences in outcomes of early- vs. late-onset patients in 
the further studies on our group of patients. Protein-
uria was by far the most frequent indication for kidney 
biopsy in our group. All patients had at least mild pro-
teinuria, and almost half of them had nephrotic range 
proteinuria. There was no difference in the degree of 
proteinuria or the frequency of nephrotic range pro-
teinuria between males and females. However, while 
not statistically significant, males in our study had a 
trend towards higher proteinuria (females vs. males, 
3.8 vs. 5.6 g/day, respectively). Yong et al. reported a 
similar finding in an Australian cohort when examin-
ing indications for renal biopsy: 85% of patients had 
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proteinuria, including 23% with nephrotic range pro-
teinuria.39 Resende et al. reported values of proteinuria 
in males similar to the values observed in our group 
(5.3 g/day).40 In a Chinese cohort of 1814 patients 
with biopsy-proven LN, proteinuria at the time of bi-
opsy was 3.08 g/day with higher values in males (fe-
males vs. males, 2.93 vs. 3.99 g/day). A total of 30.9% 
of patients had nephrotic range proteinuria at the time 
of biopsy, while 21.7% had impaired kidney function 
and 5.1% had gross hematuria.41 A relatively small 
proportion of our patients had insignificant (low-
grade) proteinuria (<0.5 g/day). A very recent study by 
De Rosa et al. comparing 46 patients with (insignifi-
cant) proteinuria of <0.5 g/day and 176 patients with 
proteinuria of higher range at the time of biopsy re-
ported that prevalence of class III was higher in the 
insignificant proteinuria group (insignificant vs. high 
proteinuria group, 30.4% vs. 10.2%, respectively). Con-
versely, class IV was less prevalent in the insignificant 
proteinuria group (45.7% vs. 76.6%, respectively).42 
The study accentuated the surprisingly high prevalence 
of proliferative LN in patients with insignificant pro-
teinuria. This is complementary to the findings of Za-
baleta-Lanz et al. demonstrating that silent LN (a dis-
tinct entity from LN with low proteinuria as defined in 
the study by De Rosa et al.) might also have a prolif-
erative histopathology, albeit less frequently than in 
overt disease, and is probably the earliest stage of LN.43 
In a study by Mavragani et al., almost a quarter of pa-
tients with proliferative LN (classes III and IV) 
(24.1%) had insignificant proteinuria (<0.5 g/day).44 
While the small number of patients with proteinuria 
of <0.5 g/day in our group precluded us from conduct-
ing a thorough analysis of the relationship of low pro-
teinuria with histopathology, the three patients with 
low proteinuria had LN class I, II and III+V, respec-
tively. Based on these results, it should be noted that 
low proteinuria at the time of biopsy does not exclude 
proliferative LN or significant renal injury in general. 
Therefore, an active urinary sediment (especially with 
urinary casts) should probably be viewed as an equally 
important indication for renal biopsy as proteinuria.45
With regard to histopathology, over 60% of our pa-
tients had proliferative LN (classes III and IV), with 
class IV predominance. This is consistent with several 
large studies. Hanly et al. examined 377 renal biopsies 
of patients with LN, revealing that 70% had classes III 
and IV with classes V, II, I, and VI following in order 
of descending frequency.33 Data from a large Chinese 
cohort similarly revealed 52.7% of patients with LN 
classes III and IV, with other classes being less com-
mon.41 A recent Japanese study reported 53.8% of pa-
tients with class III and IV, as well as 22.2% with class 
V.46 The vast majority of our LN patients were treated 
with a cyclophosphamide-based induction regimen. 
Patients with a severe clinical presentation and pro-
found proteinuria were treated according to the NIH 
induction regimen, while others underwent induction 
either with the Euro-Lupus or the MMF-based regi-
men. The higher proportion of patients treated as per 
the Euro-Lupus regimen compared to the NIH regi-
men is in line with other studies and reflects the no-
tion that lower-dose cyclophosphamide is as equally 
effective as higher dose regimens, yet with less short-
term and long-term toxicity.47–50 Possible reasons for 
the relatively low proportion of patients treated with 
MMF is the relatively higher cost of this medication 
and its consequently lower availability in our routine 
setting, especially in the first half of the observed pe-
riod (2011-2015). Furthermore, the use of intravenous 
cyclophosphamide is less associated with the issue of 
patient compliance.51 Our study had several limita-
tions. This was a retrospective study with all limitations 
and risk of bias inherent to this study type. With the 
current data analyzed in this study, we were not able to 
assess patients’ outcomes. The sample size was relative-
ly small, although comparable to a number of studies, 
and, given that the sample was obtained in a tertiary 
hospital, it might not be representative of all LN pa-
tients. However, our hospital is the national referral 
center for SLE and treats both self-referred and physi-
cian-referred patients across the country. On the other 
hand, this is a pilot study aiming to describe the popu-
lation of our LN patients over a limited time period. 
The identification of our LN cases was limited to find-
ing patients that underwent renal biopsy at our ne-
phrology unit, possibly omitting patients who under-
went kidney biopsy at another facility. Furthermore, 
this was mainly a descriptive study with no comparator 
group.
Conclusion
We have presented the main characteristics of our 
group of patients with LN diagnosed over a 10-year 
period. While there is significant heterogeneity be-
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tween different populations of LN patients, our pa-
tient profile was similar to that from a number of Eu-
ropean studies. This study will serve as a foundation for 
defining a retrospective cohort of LN patients, allow-
ing us to assess disease and renal-specific outcomes of 
patients from one of the largest referral centers in 
Southeast Europe.
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Sažetak
KLINIČKE KARAKTERISTIKE I LIJEČENJE LUPUSNOG NEFRITISA  
– PRELIMINARNA ANALIZA OPSERVACIJSKIH PODATAKA  
NACIONALNOG REFERENTNOG CENTRA
T. Knežević, I. Padjen, S. Bulimbašić, M. Ćorić, V. Ivković, M. Laganović i B. Anić
Lupusni nefritis (LN) je česta i vrlo ozbiljna manifestacija sustavnog eritemskog lupusa (SLE). Još uvijek nema dovoljno 
podataka o karakteristikama bolesnika s LN u Hrvatskoj. Analizirali smo karakteristike bolesnika s LN koji su liječeni u 
referentnom centru naše tercijarne ustanove. U ovu retrospektivnu studiju uključili smo bolesnike s biopsijom potvrđenim 
LN u periodu od 2011. do 2020. godine, analizirali smo demografske podatke, parametre bubrežne funkcije, patohistološki 
nalaz bioptata bubrega i liječenje. U studiju je uključeno 38 bolesnika (30 žena, prosječna dob 39±15godina). Najčešća indi-
kacija za biopsiju bubrega bila je proteinurija (89%). Raspodjela klasa LN bila je sljedeća: klasa I(2,6 %), II(5,3 %), III(18,4 %), 
IV(42,1 %), V(13,2 %), III+V(10,5 %), IV+V(5,3 %). Prosječno vrijeme od dijagnoze SLE do histološke potvrde LN bilo je 
1,0 godina. Svi bolesnici su liječeni kortikosteroidima, 68 % liječeno je bolusima metilprednizolona. Indukcijska terapija 
uključivala je parenteralnu primjenu ciklofosfamida (CYC) (71 %) (15 bolesnika liječeno je prema Euro-lupus protokolu, 9 
bolesnika prema protokolu Nacionalnog instituta za zdravlje (NIH)), peroralni CYC (3 %) ili mikofenolat mofetil (11 %). 
Antimalarike je primilo 79 % bolesnika. Unatoč heterogenosti između različitih populacija s LN, profil bolesnika uključen u 
ovu studiju sličan je ostalim europskim studijama. Daljnje praćenje potrebno je da bi se istražili ishodi u ovoj populaciji.
Ključne riječi: sustavni eritemski lupus, lupus nefritis, liječenje, karakteristike populacije
